TubaScan is an SME with a strong focus on developing molecular diagnostic assays on the basis of human biomarkers. It is a spin-off company from the Department of Medical Microbiology and Infection Control of the VU University Medical Center in Amsterdam. It is currently developing two diagnostic assays:

1. TubaSCAN for Chlamydia trachomatis associated infertility and tubal pathology based on host genetic markers.
2. PreselectSCAN as a biomarker Assay for prediction of clinical response to B-lymphocyte inhibiting or depleting therapies using expression levels of genes of the Type I IFN pathway to identify therapy response.

In August 2017 Tubascan officially launched CeliaSCAN, a host genetic HLA markers assay for Celiac Disease susceptibility as a CE IVD certified assay.